Taniguchi Y, Nakano M, Hasegawa S, Kanda T, Imai S, Suzuki T, Kobayashi I, Nagai R
Second Department of Internal Medicine, University of Gunma, Japan.
Res Commun Mol Pathol Pharmacol. 1996 May;92(2):201-10.
We investigated the effect of amiloride, a Na(+)-H+ exchange blocker, on ventricular hypertrophy in a murine model of dilated cardiomyopathy (DCM). Mice with DCM were given orally amiloride for 60 days. The ratio of heart weight to body weight and left ventricular cavity dimension were significantly smaller in both amiloride groups than those in furosemide and control (untreated DCM) groups (p < 0.05). The fiber diameter was significantly smaller in amiloride groups than that in furosemide group (p < 0.01). Plasma and cardiac angiotensin II (AII) levels were decreased in amiloride-treated groups compared with those in furosemide or control group (p < 0.05). Our findings suggest that amiloride prevents the development of myocardial hypertrophy and left ventricular dilatation in DCM in association with a reduction of AII.
我们研究了钠氢交换阻滞剂氨氯吡咪对扩张型心肌病(DCM)小鼠模型心室肥厚的影响。给患有DCM的小鼠口服氨氯吡咪60天。氨氯吡咪组的心脏重量与体重之比和左心室腔尺寸均显著小于速尿组和对照组(未治疗的DCM组)(p<0.05)。氨氯吡咪组的纤维直径显著小于速尿组(p<0.01)。与速尿组或对照组相比,氨氯吡咪治疗组的血浆和心脏血管紧张素II(AII)水平降低(p<0.05)。我们的研究结果表明,氨氯吡咪可预防DCM中心肌肥厚和左心室扩张的发展,这与AII的减少有关。